These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 26294796

  • 1. Mutant Cullin causes cardiovascular compromise.
    Luft FC.
    EMBO Mol Med; 2015 Oct; 7(10):1254-6. PubMed ID: 26294796
    [Abstract] [Full Text] [Related]

  • 2. Characterisation of the Cullin-3 mutation that causes a severe form of familial hypertension and hyperkalaemia.
    Schumacher FR, Siew K, Zhang J, Johnson C, Wood N, Cleary SE, Al Maskari RS, Ferryman JT, Hardege I, Yasmin, Figg NL, Enchev R, Knebel A, O'Shaughnessy KM, Kurz T.
    EMBO Mol Med; 2015 Oct; 7(10):1285-306. PubMed ID: 26286618
    [Abstract] [Full Text] [Related]

  • 3. Pseudohypoaldosteronism Type II Caused by CUL3 Mutation Presented with Visual Impairment.
    Wang Q, Cao BY, Su C, Li WJ, Gong CX.
    Chin Med J (Engl); 2018 Aug 05; 131(15):1879-1881. PubMed ID: 30058590
    [No Abstract] [Full Text] [Related]

  • 4. Pseudohypoaldosteronism type 2: CUL3 mutation confirmed 15 years following initial diagnosis.
    Li B, Soule S, Wilkinson T, Florkowski C.
    Intern Med J; 2022 Apr 05; 52(4):691-692. PubMed ID: 35419964
    [No Abstract] [Full Text] [Related]

  • 5. A case of novel mutation of Cullin 3 gene in pseudohypoaldosteronism type II.
    Wang L, Nie M, Guo F, Tian Z, Guo X, Zhang S.
    J Hypertens; 2022 Jun 01; 40(6):1239-1242. PubMed ID: 35703886
    [Abstract] [Full Text] [Related]

  • 6. A young child with pseudohypoaldosteronism type II by a mutation of Cullin 3.
    Tsuji S, Yamashita M, Unishi G, Takewa R, Kimata T, Isobe K, Chiga M, Uchida S, Kaneko K.
    BMC Nephrol; 2013 Jul 31; 14():166. PubMed ID: 23902721
    [Abstract] [Full Text] [Related]

  • 7. Familial Hyperkalemic Hypertension Genotype With a Negative Phenotype: A CUL3 Mosaicism.
    Ostrosky-Frid M, Chávez-Canales M, Romo M, Grunfeld B, Simsolo R, Segura-Kato Y, Tusié-Luna T, Gamba G.
    Am J Hypertens; 2020 Mar 13; 33(3):278-281. PubMed ID: 31802109
    [No Abstract] [Full Text] [Related]

  • 8. Decreased KLHL3 expression is involved in the pathogenesis of pseudohypoaldosteronism type II caused by cullin 3 mutation in vivo.
    Yoshida S, Araki Y, Mori T, Sasaki E, Kasagi Y, Isobe K, Susa K, Inoue Y, Bomont P, Okado T, Rai T, Uchida S, Sohara E.
    Clin Exp Nephrol; 2018 Dec 13; 22(6):1251-1257. PubMed ID: 29869755
    [Abstract] [Full Text] [Related]

  • 9. [Severity of familial hyperkalemic hypertension caused by CUL-3 mutations: a story about kidneys and blood vessels].
    Rafael C, Hadchouel J.
    Med Sci (Paris); 2020 May 13; 36(5):455-458. PubMed ID: 32452365
    [No Abstract] [Full Text] [Related]

  • 10. Mechanisms and controversies in mutant Cul3-mediated familial hyperkalemic hypertension.
    Ferdaus MZ, McCormick JA.
    Am J Physiol Renal Physiol; 2018 May 01; 314(5):F915-F920. PubMed ID: 29361671
    [Abstract] [Full Text] [Related]

  • 11. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities.
    Boyden LM, Choi M, Choate KA, Nelson-Williams CJ, Farhi A, Toka HR, Tikhonova IR, Bjornson R, Mane SM, Colussi G, Lebel M, Gordon RD, Semmekrot BA, Poujol A, Välimäki MJ, De Ferrari ME, Sanjad SA, Gutkin M, Karet FE, Tucci JR, Stockigt JR, Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML, Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW, Hunley TE, Nelson RD, Trachtman H, Cole TR, Pinsk M, Bockenhauer D, Shenoy M, Vaidyanathan P, Foreman JW, Rasoulpour M, Thameem F, Al-Shahrouri HZ, Radhakrishnan J, Gharavi AG, Goilav B, Lifton RP.
    Nature; 2012 Jan 22; 482(7383):98-102. PubMed ID: 22266938
    [Abstract] [Full Text] [Related]

  • 12. Familial cases of pseudohypoaldosteronism type II harboring a novel mutation in the Cullin 3 gene.
    Nakano K, Kubota Y, Mori T, Chiga M, Mori T, Sonoda S, Ueda D, Asakura I, Ikegaya T, Kagawa J, Uchida S, Kubota A.
    Nephrology (Carlton); 2020 Nov 22; 25(11):818-821. PubMed ID: 32619053
    [Abstract] [Full Text] [Related]

  • 13. [KLHL3 and CULLIN-3: new genes involved in familial hypertension].
    Louis-Dit-Picard H, Hadchouel J, Jeunemaitre X.
    Med Sci (Paris); 2012 Nov 22; 28(8-9):703-6. PubMed ID: 22920870
    [No Abstract] [Full Text] [Related]

  • 14. Mutant Cullin 3 causes familial hyperkalemic hypertension via dominant effects.
    Ferdaus MZ, Miller LN, Agbor LN, Saritas T, Singer JD, Sigmund CD, McCormick JA.
    JCI Insight; 2017 Dec 21; 2(24):. PubMed ID: 29263298
    [Abstract] [Full Text] [Related]

  • 15. Rare cause of severe hypertension in an adolescent boy presenting with short stature: Answers.
    Yavas Abali Z, Yesil G, Kirkgoz T, Cicek N, Alpay H, Turan S, Bereket A, Guran T.
    Pediatr Nephrol; 2020 Mar 21; 35(3):405-407. PubMed ID: 31529157
    [No Abstract] [Full Text] [Related]

  • 16. Pseudohypoaldosteronism types I and II: little more than a name in common.
    Casas-Alba D, Vila Cots J, Monfort Carretero L, Martorell Sampol L, Zennaro MC, Jeunemaitre X, Camacho Díaz JA.
    J Pediatr Endocrinol Metab; 2017 May 01; 30(5):597-601. PubMed ID: 28593901
    [Abstract] [Full Text] [Related]

  • 17. Regulation of blood pressure and renal electrolyte balance by Cullin-RING ligases.
    Uchida S.
    Curr Opin Nephrol Hypertens; 2014 Sep 01; 23(5):487-93. PubMed ID: 24992566
    [Abstract] [Full Text] [Related]

  • 18. ROMK expression remains unaltered in a mouse model of familial hyperkalemic hypertension caused by the CUL3Δ403-459 mutation.
    Murthy M, Kurz T, O'Shaughnessy KM.
    Physiol Rep; 2016 Jul 01; 4(13):. PubMed ID: 27378813
    [Abstract] [Full Text] [Related]

  • 19. Generation and analysis of a mouse model of pseudohypoaldosteronism type II caused by KLHL3 mutation in BTB domain.
    Lin CM, Cheng CJ, Yang SS, Tseng MH, Yen MT, Sung CC, Lin SH.
    FASEB J; 2019 Jan 01; 33(1):1051-1061. PubMed ID: 30148674
    [Abstract] [Full Text] [Related]

  • 20. Hyperkalemic hypertension-associated cullin 3 promotes WNK signaling by degrading KLHL3.
    McCormick JA, Yang CL, Zhang C, Davidge B, Blankenstein KI, Terker AS, Yarbrough B, Meermeier NP, Park HJ, McCully B, West M, Borschewski A, Himmerkus N, Bleich M, Bachmann S, Mutig K, Argaiz ER, Gamba G, Singer JD, Ellison DH.
    J Clin Invest; 2014 Nov 01; 124(11):4723-36. PubMed ID: 25250572
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.